Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations
Biodesix will present data from three studies at SITC's annual meeting.
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.
Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference
Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.
VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.
Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy
Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy